Treatment of canine anal furunculosis (CAF) with intralesionally injected canine Wharton’s Jelly Mesenchymal Stem Cells (WJ-MSC)

Sponsor: Private Foundation

CSRC Protocol #: 007.15

Status:  Fully enrolled

Description:

The goal of this study is to develop a new treatment for perianal fistulas in dogs.  The current treatments for this severe condition (steroids and cyclosporine) are ineffective in a high percentage of patients and the disease relapses frequently.  Also, cyclosporine is expensive and has many side effects, so a major goal is to develop a therapy which reduces the need for immunosuppressive agents, such as cyclosporine. Previous trials using intralesional injections of stem cells have shown very encouraging results.

Inclusion Criteria:                               

  • Adult dogs, any breed and either gender, with a clinical diagnosis of anal fistulas (presence of chronic peri-anal fistula(s) with clinical signs of tenesmus, dyschezia)and present with partial or complete relapse from cyclosporine A therapy
  • Age range 1-12 years
  • Weight range 2-100 kg

 

Exclusion Criteria:

  • Dogs younger than 1 year or older than 12 years
  • Other severe diseases ( severe osteoarthritis, cardiac disease, neoplasia, skin disease)
  • Dogs that have had surgery (cryosurgery, anal sac resection, tail amputation) to treat the anal fistulas

 

Client Benefits:

The study will cover all the costs of the examinations (once your dog is found eligible) and stem cell treatments including sedation.  The study will provide $300 to participants toward purchase of cyclosporine during the 1 year study.

Contact information:

For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu